Cytokinetics Sees Enough Evidence To Move Reldesemtiv Into Phase III For ALS

The Astellas-partnered drug did not reach statistical significance on any FORTITUDE-ALS endpoints, but clinically significant results over time justify a longer Phase III study that's likely to enroll ALS patients with a faster rate of disease progression.